Availability
0
Your Basket is Empty
BP165815

PTC 209 - Bio-X NEW

A small molecule inhibitor of polycomb complex protein BMI-1, a gene often overexpressed in tumors and therefore a popular therapeutic target in cancer. Anti-tumor effects of PTC 209 have been demonstrated in colorectal carcinoma, acute myeloid leukemia, multiple myeloma and head neck squamous cell carcinoma. As a regulator of self-renewal, inhibition of BMI-1 by PTC 209 also reduces growth of colorectal cancer initiating cells. 

Technical Data

CAS No: 315704-66-6
Product Code: BP165815
Chemical Formula: C17H13Br2N5OS
Molecular Weight: 495.19

References


  • Kreso A et al (2014). Self-renewal as a therapeutic target in human colorectal cancer. Nat Med 20(1):29-36.
  • Bolomsky A et al (2016). Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment. J Hematol Oncol 9:17.
  • Wang Q et al (2017). Pharmacological inhibition of Bmi1 by PTC-209 impaired tumor growth in head neck squamous cell carcinoma. Cancer Cell Int 17:107.

Solubility

Stability

Further Information


Datasheets

Specification: View
MSDS: View

PTC 209 - Bio-X

CAS No:
315704-66-6
Chemical Formula:
Molecular Weight:
495.19
Product Structure
References:
1. Kreso A et al (2014). Self-renewal as a therapeutic target in human colorectal cancer. Nat Med 20(1):29-36.
2. Bolomsky A et al (2016). Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment. J Hematol Oncol 9:17.
3. Wang Q et al (2017). Pharmacological inhibition of Bmi1 by PTC-209 impaired tumor growth in head neck squamous cell carcinoma. Cancer Cell Int 17:107.
Click for Specification
Click for MSDS

For requirements greater than the catalogue prepacks email: enquiries@carbosynth.com

Custom Synthesis

For custom synthesis or special requests email: enquiries@carbosynth.com, call +44 (0)1635 578444 or fill out our contact form

Please Wait...